EntryPoint Capital’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.27M Buy
+21,010
New +$1.22M 0.37% 24
2024
Q2
Sell
-3,501
Closed -$190K 944
2024
Q1
$190K Buy
3,501
+1,857
+113% +$94.6K 0.17% 128
2023
Q4
$84.4K Buy
+1,644
New +$86.3K 0.08% 465

Other funds holding BMY

EntryPoint Capital's BMY Position: Q1 2026 in Review

EntryPoint Capital opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 21,010 shares worth $1.27M. The stake represents 0.37% of the portfolio and ranks #24 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in BMY as recently as Q1 2024.

EntryPoint Capital first reported a position in BMY in Q4 2023 and has held it in 3 quarters since. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • EntryPoint Capital held 21,010 shares of Bristol-Myers Squibb worth $1.27M as of Q1 2026.
  • Bristol-Myers Squibb was a new EntryPoint Capital position in Q1 2026.
  • Bristol-Myers Squibb made up 0.37% of EntryPoint Capital's portfolio in Q1 2026, its #24 holding.
  • EntryPoint Capital first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 3 quarters since.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.